Skip to main content
SpringerLink
Log in

Bronchiolitis Obliterans Syndrome

  • Chapter
  • First Online:
Pulmonary and Critical Care Considerations of Hematopoietic Stem Cell Transplantation

  • 430 Accesses

Abstract

Bronchiolitis obliterans (BO) is the only late-onset pulmonary complication after allogeneic hematopoietic stem cell transplantation (HSCT) to be recognized as a pulmonary graft-versus-host disease, affecting approximately 10% of HSCT recipients. Although the diagnosis of BO used to require a lung biopsy, it is now based primarily on pulmonary function tests and is called bronchiolitis obliterans syndrome (BOS). However, there are subtypes of BOS with different respiratory function profiles. Similarly, BOS may correspond to different histological subtypes. Unfortunately, there is no curative treatment for BOS. In addition to a better understanding of the pathophysiology of BOS, current research aims to identify biomarkers capable of diagnosing BOS at an early stage where treatment would be more effective.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Roca J, Grañeña A, Rodriguez-Roisin R, Alvarez P, Agusti-Vidal A, Rozman C. Fatal airway disease in an adult with chronic graft-versus-host disease. Thorax. 1982;37(1):77–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Barker AF, Bergeron A, Rom WN, Hertz MI. Obliterative bronchiolitis. N Engl J Med. 2014;370(19):1820–8.

    Article  CAS  PubMed  Google Scholar 

  3. Bos S, Beeckmans H, Vanstapel A, Sacreas A, Geudens V, Willems L, et al. Pulmonary graft-versus-host disease and chronic lung allograft dysfunction: two sides of the same coin? Lancet Respir Med. 2022;10:796.

    Article  PubMed  Google Scholar 

  4. Solh M, Arat M, Cao Q, Majhail NS, Weisdorf D. Late-onset noninfectious pulmonary complications in adult allogeneic hematopoietic cell transplant recipients. Transplantation. 2011;91(7):798–803.

    Article  PubMed  Google Scholar 

  5. Clark JG, Crawford SW, Madtes DK, Sullivan KM. Obstructive lung disease after allogeneic marrow transplantation. Clinical presentation and course. Ann Intern Med. 1989;111(5):368–76.

    Article  CAS  PubMed  Google Scholar 

  6. Chan CK, Hyland RH, Hutcheon MA, Minden MD, Alexander MA, Kossakowska AE, et al. Small-airways disease in recipients of allogeneic bone marrow transplants. An analysis of 11 cases and a review of the literature. Medicine (Baltimore). 1987;66(5):327–40.

    Article  CAS  PubMed  Google Scholar 

  7. Marras TK, Szalai JP, Chan CK, Lipton JH, Messner HA, Laupacis A. Pulmonary function abnormalities after allogeneic marrow transplantation: a systematic review and assessment of an existing predictive instrument. Bone Marrow Transplant. 2002;30(9):599–607.

    Article  CAS  PubMed  Google Scholar 

  8. Dudek AZ, Mahaseth H, DeFor TE, Weisdorf DJ. Bronchiolitis obliterans in chronic graft-versus-host disease: analysis of risk factors and treatment outcomes. Biol Blood Marrow Transplant. 2003;9(10):657–66.

    Article  PubMed  Google Scholar 

  9. Chien JW, Martin PJ, Gooley TA, Flowers ME, Heckbert SR, Nichols WG, et al. Airflow obstruction after myeloablative allogeneic hematopoietic stem cell transplantation. Am J Respir Crit Care Med. 2003;168(2):208–14.

    Article  PubMed  Google Scholar 

  10. Abedin S, Yanik GA, Braun T, Pawarode A, Magenau J, Goldstein SC, et al. Predictive value of bronchiolitis obliterans syndrome stage 0p in chronic graft-versus-host disease of the lung. Biol Blood Marrow Transplant. 2015;21(6):1127–31.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Au BK, Au MA, Chien JW. Bronchiolitis obliterans syndrome epidemiology after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2011;17(7):1072–8.

    Article  PubMed  Google Scholar 

  12. Ditschkowski M, Elmaagacli AH, Koldehoff M, Gromke T, Trenschel R, Beelen DW. Bronchiolitis obliterans after allogeneic hematopoietic SCT: further insight—new perspectives? Bone Marrow Transplant. 2013;48(9):1224–9.

    Article  CAS  PubMed  Google Scholar 

  13. Bergeron A, Godet C, Chevret S, Lorillon G, Peffault de Latour R, de Revel T, et al. Bronchiolitis obliterans syndrome after allogeneic hematopoietic SCT: phenotypes and prognosis. Bone Marrow Transplant. 2013;48(6):819–24.

    Article  CAS  PubMed  Google Scholar 

  14. Duque-Afonso J, Ihorst G, Wäsch R, Bertz H, Müller-Quernheim J, Finke J, et al. Identification of risk factors for bronchiolitis obliterans syndrome after reduced toxicity conditioning before hematopoietic cell transplantation. Bone Marrow Transplant. 2013;48(8):1098–103.

    Article  CAS  PubMed  Google Scholar 

  15. Bergeron A, Chevret S, Peffault de Latour R, Chagnon K, de Margerie-Mellon C, Rivière F, et al. Noninfectious lung complications after allogeneic haematopoietic stem cell transplantation. Eur Respir J. 2018;51(5):1702617.

    Article  PubMed  Google Scholar 

  16. Vieira AG, Funke VA, Nunes EC, Frare R, Pasquini R. Bronchiolitis obliterans in patients undergoing allogeneic hematopoietic SCT. Bone Marrow Transplant. 2014;49(6):812–7.

    Article  CAS  PubMed  Google Scholar 

  17. Touihri M, Torjeman L, Kaabi H, Chabaane M, Othman TB, Hmida S. Bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation: the effect of NOD2/CARD15 mutations in a Tunisian population. Hum Immunol. 2019;80(3):163–8.

    Article  CAS  PubMed  Google Scholar 

  18. Chien JW, Zhao LP, Hansen JA, Fan WH, Parimon T, Clark JG. Genetic variation in bactericidal/permeability-increasing protein influences the risk of developing rapid airflow decline after hematopoietic cell transplantation. Blood. 2006;107(5):2200–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Alexander KA, Flynn R, Lineburg KE, Kuns RD, Teal BE, Olver SD, et al. CSF-1-dependant donor-derived macrophages mediate chronic graft-versus-host disease. J Clin Invest. 2014;124(10):4266–80.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Kuroi T, Fujii N, Ichimura K, Seike K, Yamamoto A, Kambara Y, et al. Characterization of localized macrophages in bronchiolitis obliterans after allogeneic hematopoietic cell transplantation. Int J Hematol. 2021;114(6):701–8.

    Article  CAS  PubMed  Google Scholar 

  21. Flynn R, Du J, Veenstra RG, Reichenbach DK, Panoskaltsis-Mortari A, Taylor PA, et al. Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans. Blood. 2014;123(25):3988–98.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Kuzmina Z, Krenn K, Petkov V, Körmöczi U, Weigl R, Rottal A, et al. CD19(+)CD21(low) B cells and patients at risk for NIH-defined chronic graft-versus-host disease with bronchiolitis obliterans syndrome. Blood. 2013;121(10):1886–95.

    Article  CAS  PubMed  Google Scholar 

  23. Nakasone H, Kanda J, Yano S, Atsuta Y, Ago H, Fukuda T, et al. A case-control study of bronchiolitis obliterans syndrome following allogeneic hematopoietic stem cell transplantation. Transpl Int. 2013;26(6):631–9.

    Article  PubMed  Google Scholar 

  24. Santo Tomas LH, Loberiza FR Jr, Klein JP, Layde PM, Lipchik RJ, Rizzo JD, et al. Risk factors for bronchiolitis obliterans in allogeneic hematopoietic stem-cell transplantation for leukemia. Chest. 2005;128(1):153–61.

    Article  PubMed  Google Scholar 

  25. Gazourian L, Rogers AJ, Ibanga R, Weinhouse GL, Pinto-Plata V, Ritz J, et al. Factors associated with bronchiolitis obliterans syndrome and chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation. Am J Hematol. 2014;89(4):404–9.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Erard V, Chien JW, Kim HW, Nichols WG, Flowers ME, Martin PJ, et al. Airflow decline after myeloablative allogeneic hematopoietic cell transplantation: the role of community respiratory viruses. J Infect Dis. 2006;193(12):1619–25.

    Article  PubMed  Google Scholar 

  27. Sheshadri A, Chemaly RF, Alousi AM, Shah PK, Rondon G, Bashoura L, et al. Pulmonary impairment after respiratory viral infections is associated with high mortality in allogeneic hematopoietic cell transplant recipients. Biol Blood Marrow Transplant. 2019;25(4):800–9.

    Article  PubMed  Google Scholar 

  28. Scheidl S, Zinke-Cerwenka W, Flick H, Gaal S, Avian A, Greinix H, et al. Whole-body lung function test-derived outcome predictors in allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2019;25(1):129–36.

    Article  PubMed  Google Scholar 

  29. Jamani K, He Q, Liu Y, Davis C, Hubbard J, Schoch G, et al. Early post-transplantation spirometry is associated with the development of bronchiolitis obliterans syndrome after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2020;26(5):943–8.

    Article  PubMed  Google Scholar 

  30. Snowden JA, Sánchez-Ortega I, Corbacioglu S, Basak GW, Chabannon C, de la Camara R, et al. Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. Bone Marrow Transplant. 2022;57:1217–39.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Dirou S, Malard F, Chambellan A, Chevallier P, Germaud P, Guillaume T, et al. Stable long-term pulmonary function after fludarabine, antithymocyte globulin and i.v. BU for reduced-intensity conditioning allogeneic SCT. Bone Marrow Transplant. 2014;49(5):622–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Yousem SA. The histological spectrum of pulmonary graft-versus-host disease in bone marrow transplant recipients. Hum Pathol. 1995;26(6):668–75.

    Article  CAS  PubMed  Google Scholar 

  33. Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant. 2015;21(3):389–401.e1.

    Article  PubMed  Google Scholar 

  34. Shulman HM, Cardona DM, Greenson JK, Hingorani S, Horn T, Huber E, et al. NIH Consensus development project on criteria for clinical trials in chronic graft-versus-host disease: II. The 2014 Pathology Working Group Report. Biol Blood Marrow Transplant. 2015;21(4):589–603.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Wolff D, Radojcic V, Lafyatis R, Cinar R, Rosenstein RK, Cowen EW, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2020 Highly morbid forms report. Transplant Cell Ther. 2021;27(10):817–35.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Holbro A, Lehmann T, Girsberger S, Stern M, Gambazzi F, Lardinois D, et al. Lung histology predicts outcome of bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2013;19(6):973–80.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Meignin V, Thivolet-Bejui F, Kambouchner M, Hussenet C, Bondeelle L, Mitchell A, et al. Lung histopathology of non-infectious pulmonary complications after allogeneic haematopoietic stem cell transplantation. Histopathology. 2018;73(5):832–42.

    Article  PubMed  Google Scholar 

  38. Carpenter PA, Kitko CL, Elad S, Flowers ME, Gea-Banacloche JC, Halter JP, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant. 2015;21(7):1167–87.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Sheshadri A, Sacks NC, Healey BE, Raza S, Boerner G, Huang HJ. Lung function monitoring after lung transplantation and allogeneic hematopoietic stem cell transplantation. Clin Ther. 2022;44:755.

    Article  PubMed  Google Scholar 

  40. Turner J, He Q, Baker K, Chung L, Lazarevic-Fogelquist A, Bethune D, et al. Home spirometry telemonitoring for early detection of bronchiolitis obliterans syndrome in patients with chronic graft-versus-host disease. Transplant Cell Ther. 2021;27(7):616.e1–6.

    Article  PubMed  Google Scholar 

  41. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11(12):945–56.

    Article  PubMed  Google Scholar 

  42. Uhlving HH, Andersen CB, Christensen IJ, Gormsen M, Pedersen KD, Buchvald F, et al. Biopsy-verified bronchiolitis obliterans and other noninfectious lung pathologies after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2015;21(3):531–8.

    Article  PubMed  Google Scholar 

  43. Wan ES, Balte P, Schwartz JE, Bhatt SP, Cassano PA, Couper D, et al. Association between preserved ratio impaired spirometry and clinical outcomes in US adults. JAMA. 2021;326(22):2287–98.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Thompson PA, Lim A, Panek-Hudson Y, Tacey M, Hijazi R, Ng AP, et al. Screening with spirometry is a useful predictor of later development of noninfectious pulmonary syndromes in patients undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2014;20(6):781–6.

    Article  PubMed  Google Scholar 

  45. Peha M. In: Med AJRC, editor. Detection of FEV1 decline preceding bronchiolitis obliterans syndrome diagnosis in allogeneic hematopoietic stem cell transplant recipients. San Francisco: ATS; 2022.

    Chapter  Google Scholar 

  46. Myrdal OH, Aaløkken TM, Diep PP, Ruud E, Brinch L, Fosså K, et al. Late-onset, noninfectious pulmonary complications following allogeneic hematopoietic stem cell transplantation: a nationwide cohort study of long-term survivors. Respiration. 2022;101(6):544–52.

    Article  CAS  PubMed  Google Scholar 

  47. Zompatori M, Fasano L, Fabbri M, Maraldi F, Carvelli P, Laporta T, et al. Assessment of the severity of pulmonary emphysema by computed tomography. Monaldi Arch Chest Dis. 1997;52(2):147–54.

    CAS  PubMed  Google Scholar 

  48. Sharifi H, Guenther ZD, Leung ANC, Johnston L, Lai YK, Hsu JL, et al. Head-to-head comparison of qualitative radiologist assessment with automated quantitative computed tomography analysis for bronchiolitis obliterans syndrome after hematopoietic cell transplantation. J Thorac Imaging. 2022;37(2):109–16.

    Article  PubMed  Google Scholar 

  49. Cheng GS, Selwa KE, Hatt C, Ram S, Fortuna AB, Guerriero M, et al. Multicenter evaluation of parametric response mapping as an indicator of bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation. Am J Transplant. 2020;20(8):2198–205.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Pham J, Rangaswamy J, Avery S, Borg B, Martin C, Munsif M, et al. Updated prevalence, predictors and treatment outcomes for bronchiolitis obliterans syndrome after allogeneic stem cell transplantation. Respir Med. 2020;177:106286.

    Article  PubMed  Google Scholar 

  51. Cheng GS, Storer B, Chien JW, Jagasia M, Hubbard JJ, Burns L, et al. Lung function trajectory in bronchiolitis obliterans syndrome after allogeneic hematopoietic cell transplant. Ann Am Thorac Soc. 2016;13(11):1932–9.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Sacks NC, Healey BE, Raza S, Cyr PL, Boerner G, Sheshadri A. The economic burden of NIPC and BOS following allogeneic HSCT in patients with commercial insurance in the United States. Blood Adv. 2022;6(5):1566–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Kwok WC, Liang BM, Lui MMS, Tam TCC, Sim JPY, Tse EWC, et al. Rapid versus gradual lung function decline in bronchiolitis obliterans syndrome after haematopoietic stem cell transplantation is associated with survival outcome. Respirology. 2019;24(5):459–66.

    Article  PubMed  Google Scholar 

  54. Norman BC, Jacobsohn DA, Williams KM, Au BK, Au MA, Lee SJ, et al. Fluticasone, azithromycin and montelukast therapy in reducing corticosteroid exposure in bronchiolitis obliterans syndrome after allogeneic hematopoietic SCT: a case series of eight patients. Bone Marrow Transplant. 2011;46(10):1369–73.

    Article  CAS  PubMed  Google Scholar 

  55. Busca A, Locatelli F, Marmont F, Ceretto C, Falda M. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. Am J Hematol. 2007;82(1):45–52.

    Article  CAS  PubMed  Google Scholar 

  56. Olivieri A, Locatelli F, Zecca M, Sanna A, Cimminiello M, Raimondi R, et al. Imatinib for refractory chronic graft-versus-host disease with fibrotic features. Blood. 2009;114(3):709–18.

    Article  CAS  PubMed  Google Scholar 

  57. Kim SJ, Lee JW, Jung CW, Min CK, Cho B, Shin HJ, et al. Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II study. Haematologica. 2010;95(11):1935–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Zeiser R, Burchert A, Lengerke C, Verbeek M, Maas-Bauer K, Metzelder SK, et al. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia. 2015;29(10):2062–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Zeiser R, Polverelli N, Ram R, Hashmi SK, Chakraverty R, Middeke JM, et al. Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease. N Engl J Med. 2021;385(3):228–38.

    Article  CAS  PubMed  Google Scholar 

  60. Cutler C, Lee SJ, Arai S, Rotta M, Zoghi B, Lazaryan A, et al. Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar study. Blood. 2021;138(22):2278–89.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Miklos D, Cutler CS, Arora M, Waller EK, Jagasia M, Pusic I, et al. Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. Blood. 2017;130(21):2243–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Doki N, Toyosaki M, Shiratori S, Osumi T, Okada M, Kawakita T, et al. An open-label, single-arm, multicenter study of ibrutinib in japanese patients with steroid-dependent/refractory chronic graft-versus-host disease. Transplant Cell Ther. 2021;27(10):867.e1–9.

    Article  CAS  PubMed  Google Scholar 

  63. Wertheimer T, Dohse M, Afram G, Weber D, Heidenreich M, Holler B, et al. Abatacept as salvage therapy in chronic graft-versus-host disease—a retrospective analysis. Ann Hematol. 2021;100(3):779–87.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Koshy AG, Kim HT, Stroopinsky D, Liegel JJ, Arnason JE, Ho VT, et al. Phase II clinical trial of abatacept for steroid-refractory chronic graft versus host disease. Blood. 2021;138(Supplement 1):264.

    Article  Google Scholar 

  65. Lazaryan A, Lee S, Arora M, Kim J, Betts BC, Khimani F, et al. A phase 2 multicenter trial of ofatumumab and prednisone as initial therapy for chronic graft-versus-host disease. Blood Adv. 2022;6(1):259–69.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Lee SJ, Wolff D, Kitko C, Koreth J, Inamoto Y, Jagasia M, et al. Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report. Biol Blood Marrow Transplant. 2015;21(6):984–99.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Lam DC, Lam B, Wong MK, Lu C, Au WY, Tse EW, et al. Effects of azithromycin in bronchiolitis obliterans syndrome after hematopoietic SCT—a randomized double-blinded placebo-controlled study. Bone Marrow Transplant. 2011;46(12):1551–6.

    Article  CAS  PubMed  Google Scholar 

  68. Khalid M, Al Saghir A, Saleemi S, Al Dammas S, Zeitouni M, Al Mobeireek A, et al. Azithromycin in bronchiolitis obliterans complicating bone marrow transplantation: a preliminary study. Eur Respir J. 2005;25(3):490–3.

    Article  CAS  PubMed  Google Scholar 

  69. Bergeron A, Chevret S, Chagnon K, Godet C, Bergot E, Peffault de Latour R, et al. Budesonide/Formoterol for bronchiolitis obliterans after hematopoietic stem cell transplantation. Am J Respir Crit Care Med. 2015;191(11):1242–9.

    Article  CAS  PubMed  Google Scholar 

  70. Purev E, Gormley N, Ramos C, Reger R, Tian X, Cho E, et al. Inhaled cyclosporine solution for the treatment of bronchiolitis obliterans following hematopoietic stem cell transplantation (HSCT) or lung transplantation. Biol Blood Marrow Transplant. 2015;21(2, Supplement):S347–S8.

    Article  Google Scholar 

  71. Gormley N, Ramos C, Reger R, Tropea M, Tian X, Cho E, et al. Inhaled cyclosporine for the treatment of bronchiolitis obliterans following hematopoietic stem cell transplantation (HSCT) or lung transplantation. Blood. 2013;122(21):2057.

    Article  Google Scholar 

  72. Lucid CE, Savani BN, Engelhardt BG, Shah P, Clifton C, Greenhut SL, et al. Extracorporeal photopheresis in patients with refractory bronchiolitis obliterans developing after allo-SCT. Bone Marrow Transplant. 2011;46(3):426–9.

    Article  CAS  PubMed  Google Scholar 

  73. Del Fante C, Perotti C. Extracorporeal photopheresis for bronchiolitis obliterans syndrome after allogeneic stem cell transplant: an emerging therapeutic approach? Transfus Apher Sci. 2017;56(1):17–9.

    Article  PubMed  Google Scholar 

  74. Brownback KR, Simpson SQ, Pitts LR, Polineni D, McGuirk JP, Ganguly S, et al. Effect of extracorporeal photopheresis on lung function decline for severe bronchiolitis obliterans syndrome following allogeneic stem cell transplantation. J Clin Apher. 2016;31(4):347–52.

    Article  PubMed  Google Scholar 

  75. Hefazi M, Langer KJ, Khera N, Adamski J, Roy V, Winters JL, et al. Extracorporeal photopheresis improves survival in hematopoietic cell transplant patients with bronchiolitis obliterans syndrome without significantly impacting measured pulmonary functions. Biol Blood Marrow Transplant. 2018;24(9):1906–13.

    Article  PubMed  Google Scholar 

  76. Bashoura L, Gupta S, Jain A, Couriel DR, Komanduri KV, Eapen GA, et al. Inhaled corticosteroids stabilize constrictive bronchiolitis after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2008;41(1):63–7.

    Article  CAS  PubMed  Google Scholar 

  77. Ratjen F, Rjabko O, Kremens B. High-dose corticosteroid therapy for bronchiolitis obliterans after bone marrow transplantation in children. Bone Marrow Transplant. 2005;36(2):135–8.

    Article  CAS  PubMed  Google Scholar 

  78. Even-Or E, Ghandourah H, Ali M, Krueger J, Wall DA, Sweezey NB, et al. Efficacy of high dose steroids for bronchiolitis obliterans syndrome post pediatric hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2017;23(3):S270.

    Article  Google Scholar 

  79. Stadler M, Ahlborn R, Kamal H, Diedrich H, Buchholz S, Eder M, et al. Limited efficacy of imatinib in severe pulmonary chronic graft-versus-host disease. Blood. 2009;114(17):3718–9.

    Article  CAS  PubMed  Google Scholar 

  80. Faraci M, Ricci E, Bagnasco F, Pierri F, Giardino S, Girosi D, et al. Imatinib melylate as second-line treatment of bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation in children. Pediatr Pulmonol. 2020;55(3):631–7.

    Article  PubMed  Google Scholar 

  81. Williams KM, Pavletic SZ, Lee SJ, Martin PJ, Farthing DE, Hakim FT, et al. Prospective phase II trial of montelukast to treat bronchiolitis obliterans syndrome after hematopoietic cell transplantation and investigation into bronchiolitis obliterans syndrome pathogenesis. Transplant Cell Ther. 2022;28(5):264.e1–9.

    Article  CAS  PubMed  Google Scholar 

  82. Tang W, Yu T, Dong T, Liu T, Ji J. Nintedanib in bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation. Chest. 2020;158(3):e89–91.

    Article  CAS  PubMed  Google Scholar 

  83. Matthaiou EI, Sharifi H, O'Donnell C, Chiu W, Owyang C, Chatterjee P, et al. The safety and tolerability of pirfenidone for bronchiolitis obliterans syndrome after hematopoietic cell transplant (STOP-BOS) trial. Bone Marrow Transplant. 2022;57:1319.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Lorillon G, Robin M, Meignin V, Ribaud P, Lescoeur B, Gossot D, et al. Rituximab in bronchiolitis obliterans after haematopoietic stem cell transplantation. Eur Respir J. 2011;38(2):470–2.

    Article  CAS  PubMed  Google Scholar 

  85. Zhao Y, OuYang G, Shi J, Luo Y, Tan Y, Yu J, et al. Salvage therapy with low-dose ruxolitinib leads to a significant improvement in bronchiolitis obliterans syndrome in patients with cGVHD after allogeneic hematopoietic stem cell transplantation. Front Pharmacol. 2021;12:668825.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  86. Williams KM, Cheng GS, Pusic I, Jagasia M, Burns L, Ho VT, et al. Fluticasone, azithromycin, and montelukast treatment for new-onset bronchiolitis obliterans syndrome after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2016;22(4):710–6.

    Article  CAS  PubMed  Google Scholar 

  87. Kim SW, Rhee CK, Kim YJ, Lee S, Kim HJ, Lee JW. Therapeutic effect of budesonide/formoterol, montelukast and N-acetylcysteine for bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation. Respir Res. 2016;17(1):63.

    Article  PubMed  PubMed Central  Google Scholar 

  88. Lim J, Silvia P, Kim HJ. Efficacy of inhaled tiotropium add-on to budesonide/formoterol in patients with bronchiolitis obliterans developing after hematopoietic stem cell transplantation. 2022. https://doi.org/10.21203/rs.3.rs-1678517/v1.

  89. Choi HE, Lim SN, Lee JH, Park SH. Comprehensive pulmonary rehabilitation in patients with bronchiolitis obliterans syndrome: a case series. Respir Med Case Rep. 2020;31:101161.

    PubMed  PubMed Central  Google Scholar 

  90. Chen S, Zhao K, Lin R, Wang S, Fan Z, Huang F, et al. The efficacy of mesenchymal stem cells in bronchiolitis obliterans syndrome after allogeneic HSCT: a multicenter prospective cohort study. EBioMedicine. 2019;49:213–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  91. Greer M, Berastegui C, Jaksch P, Benden C, Aubert J, Roux A, et al. Lung transplantation after allogeneic stem cell transplantation: a pan-European experience. Eur Respir J. 2018;51(2):1701330.

    Article  PubMed  Google Scholar 

  92. Riddell P, Vasudevan-Nampoothiri R, Ma J, Singer LG, Lipton JH, Juvet SC. Lung transplantation for late-onset non-infectious chronic pulmonary complications of allogeneic hematopoietic stem cell transplant. Respir Res. 2021;22(1):101.

    Article  PubMed  PubMed Central  Google Scholar 

  93. Bergeron A, Chevret S, Granata A, Chevallier P, Vincent L, Huynh A, et al. Effect of azithromycin on airflow decline-free survival after allogeneic hematopoietic stem cell transplant: the ALLOZITHRO randomized clinical trial. JAMA. 2017;318(6):557–66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  94. Cheng GS, Bondeelle L, Gooley T, He Q, Jamani K, Krakow EF, et al. Azithromycin use and increased cancer risk among patients with bronchiolitis obliterans after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2020;26(2):392–400.

    Article  CAS  PubMed  Google Scholar 

  95. Sheshadri A, Saliba R, Patel B, Ahmed T, Bueno LC, Arain MH, et al. Azithromycin may increase hematologic relapse rates in matched unrelated donor hematopoietic cell transplant recipients who receive anti-thymocyte globulin, but not in most other recipients. Bone Marrow Transplant. 2021;56(3):745–8.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Faculty of Medicine, University of Geneva, Geneva, Switzerland

    Louise Bondeelle & Anne Bergeron

  2. Service de Pneumologie, Hôpitaux Universitaires de Genève, University of Geneva, Genève, Switzerland

    Anne Bergeron

Authors
  1. Louise Bondeelle
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anne Bergeron
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anne Bergeron .

Editor information

Editors and Affiliations

  1. Pulmonary and Critical Care Medicine, Wayne State University, Detroit, MI, USA

    Ayman O. Soubani

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Bondeelle, L., Bergeron, A. (2023). Bronchiolitis Obliterans Syndrome. In: Soubani, A.O. (eds) Pulmonary and Critical Care Considerations of Hematopoietic Stem Cell Transplantation. Springer, Cham. https://doi.org/10.1007/978-3-031-28797-8_17

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-28797-8_17

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-28796-1

  • Online ISBN: 978-3-031-28797-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation